β-glucans and cholesterol (Review)

International Journal of Molecular Medicine

Volumn 41, Issue 4, 2018, Pages 1799-1808

  Sima, Petr ^a   Vannucci, Luca ^a   Vetvicka, Vaclav ^b  

^a INSTITUTE OF MATHEMATICS   (Czech Republic)

^b University of Louisville School of Medicine   (United States)

Author keywords

Cholesterol; Diabetes; Diet; Disease; Fiber; Obesity; Glucans

Indexed keywords

BETA GLUCAN; BILE ACID; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; IMMUNOLOGIC FACTOR;

CHOLESTEROL BLOOD LEVEL; DIET SUPPLEMENTATION; DIETARY FIBER; HUMAN; HYPOCHOLESTEROLEMIA; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANALYSIS; ANIMAL; BLOOD; CHEMISTRY; DRUG THERAPY; HYPERCHOLESTEROLEMIA; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BETA-GLUCANS; CHOLESTEROL; DIETARY FIBER; HUMANS; HYPERCHOLESTEROLEMIA; IMMUNOLOGIC FACTORS;

EID: 85041557156     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2018.3411     Document Type: Review

References (164)

1. World Health Organization: Cardiovascular disease. 2016.
2. World Health Organization: Obesity and overweight fact sheet. 2017.
3. World Health Organization: Obesity and overweight fact sheet. 2016.
4. CDC , National Center for Chronic Disease Prevention and Health Promotion and Division for Heart Disease and Stroke Prevention: Heart Disease Facts and Statistics. CDC .
5. Murray C J and Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349: 1498-1504, 1997.
6. Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM and McAlister FA: Body mass index and mortality in heart failure: A meta-Analysis. Am Heart J 156: 13-22, 2008.
7. Clark JM and Brancati FL: The challenge of obesity-related chronic diseases. J Gen Intern Med 15: 828-829, 2000.
8. Oreopoulos A, Ezekowitz JA, McAlister FA, Kalantar-Zadeh K, Fonarow GC, Norris CM, Johnson JA and Padwal RS: Association between direct measures of body composition and prognostic factors in chronic heart failure. Mayo Clin Proc 85: 609-617, 2010.
9. Bose KS, Gupta SK and Vyas P: Adipocytokine levels in genetically high risk for type 2 diabetes in the Indian population: A cross-sectional study. Exp Diabetes Res 2012: 386524, 2012.
10. Olson NC, Callas PW, Hanley AJ, Festa A, Haffner SM, Wagenknecht LE and Tracy RP: Circulating levels of TNF-α are associated with impaired glucose tolerance, increased insulin resistance, and ethnicity: The insulin resistance atherosclerosis study. J Clin Endocrinol Metab 97: 1032-1040, 2012.
11. Libby P, Ridker PM and Maseri A: Inflammation and atherosclerosis. Circulation 105: 1135-1143, 2002.
12. Emanuela F, Grazia M, Marco de R, Maria Paola L, Giorgio F and Marco B: Inflammation as a link between obesity and metabolic syndrome. J Nutr Metab 2012: 476380, 2012.
13. Harland JI: Food combinations for cholesterol lowering. Nutr Res Rev 25: 249-266, 2012.
14. Johnston TP, Korolenko TA, Pirro M and Sahebkar A: Preventing cardiovascular heart disease: Promising nutraceutical and non-nutraceutical treatments for cholesterol management. Pharmacol Res 120: 219-225, 2017.
15. Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C , Hatzitolios A and Giannoglou GD: Risk factors and drug interactions predisposing to statin-induced myopathy: Implications for risk assessment, prevention and treatment. Drug Saf 33: 171-187, 2010.
16. Camerino GM, Musumeci O, Conte E, Musaraj K, Fonzino A, Barca E, Marino M, Rodolico C, Tricarico D, Camerino C, et al: Risk of myopathy in patients in therapy with statins: Identification of biological markers in a pilot study. Front Pharmacol 8: 500, 2017.
17. Caparros-Martin JA, Lareu RR, Ramsay JP, Peplies J, Reen FJ, Headlam HA, Ward NC, Croft KD, Newsholme P, Hughes JD, et al: Statin therapy causes gut dysbiosis in mice through a PXR-dependent mechanism. Microbiome 5: 95, 2017.
18. Verhaegh BP, de Vries F, Masclee AA, Keshavarzian A, de Boer A, Souverein PC, Pierik MJ and Jonkers DM: High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment Pharmacol Ther 43: 1004-1013, 2016.
19. O'Keefe SJ: Diet, microorganisms and their metabolites, and colon cancer. Nat Rev Gastroenterol Hepatol 13: 691-706, 2016.
20. Peters U, Sinha R, Chatterjee N, Subar AF, Ziegler RG, Kulldorff M, Bresalier R, Weissfeld JL, Flood A, Schatzkin A, et al: Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme. Lancet 361: 1491-1495, 2003.
21. Mao QQ, Lin YW, Chen H, Qin J, Zheng XY, Xu X and Xie LP: Dietary fiber intake is inversely associated with risk of pancreatic cancer: A meta-Analysis. Asia Pac J Clin Nutr 26: 89-96, 2017.
22. Ohira H, Tsutsui W and Fujioka Y: Are short chain fatty acids in hut microbiota defensive players for inflammation and atherosclerosis? J Atheroscler Thromb 24: 660-672, 2017.
23. Hernandez-Rodas MC, Valenzuela R and Videla LA: Relevant aspects of nutritional and dietary interventions in non-Alcoholic fatty liver disease. Int J Mol Sci 16: 25168-25198, 2015.
24. Burton-Freeman B, Liyanage D , Rahman S and Edirisinghe I: Ratios of soluble and insoluble dietary fibers on satiety and energy intake in overweight pre-And postmenopausal women. Nutr Healthy Aging 4: 157-168, 2017.
25. Adam CL, Thomson LM, Williams PA and Ross AW: Soluble fermentable dietary fibre (Pectin) decreases caloric intake, adiposity and lipidaemia in high-fat diet-induced obese rats. PLoS One 10: e0140392, 2015.
26. Torcello-Gómez A, Fernández Fraguas C, Ridout MJ, Woodward NC, Wilde PJ and Foster TJ: Effect of substituent pattern and molecular weight of cellulose ethers on interactions with different bile salts. Food Funct 6: 730-739, 2015.
27. Meneses ME, Martinez-C arrera D, Torres N, Sánchez-Tapia M, Aguilar-López M, Morales P, Sobal M, Bernabé T, Escudero H, Granados-Portillo O and Tovar AR: Hypocholesterolemic properties and prebiotic effects of Mexican Ganoderma lucidum in C57BL/6 mice. PLoS One 11: e0159631, 2016.
28. Hung TV and Suzuki T: Dietary fermentable fiber reduces intestinal barrier defects and inflammation in colitic mice. J Nutr 146: 1970-1979, 2016.
29. Zhong Y, Marungruang N, Fak F and Nyman M: Effects of two whole-grain barley varieties on caecal SCFA, gut microbiota and plasma inflammatory markers in rats consuming low-And high-fat diets. Br J Nutr 113: 1558-1570, 2015.
30. Luo Y, Zhang L, Li H, Smidt H, Wright AG, Zhang K, Ding X, Zeng Q, Bai S, Wang J, et al: Different types of dietary fibers trigger specific alterations in composition and predicted functions of colonic bacterial communities in BALB/c mice. Front Microbiol 8: 966, 2017.
31. Winglee K and Fodor AA: Intrinsic association between diet and the gut microbiome: Current evidence. Nutr Diet Suppl 7: 69-76, 2015.
32. Jakobsdottir G, Xu J, Molin G, Ahrné S and Nyman M: High-fat diet reduces the formation of butyrate, but increases succinate, inflammation, liver fat and cholesterol in rats, while dietary fibre counteracts these effects. PLoS One 8: e80476, 2013.
33. Vannucci L, Krizan J, Sima P, Stakheev D , Caja F, Rajsiglova L, Horak V and Saieh M: Immunostimulatory properties and antitumor activities of glucans (Review). Int J Oncol 43: 357-364, 2013.
34. Chanput W, Reitsma M, Kleinjans L, Mes JJ, Savelkoul HF and Wichers HJ: β-Glucans are involved in immune-modulation of THP-1 macrophages. Mol Nutr Food Res 56: 822-833, 2012.
35. Ho HV, Sievenpiper JL, Zurbau A, Blanco Mejia S, Jovanovski E, Au-Yeung F, Jenkins AL and Vuksan V: The effect of oat β-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: A systematic review and meta-Analysis of randomized-controlled trials. Br J Nutr 116: 1369-1382, 2016.
36. Caz V, Gil-Ramirez A, Largo C, Tabernero M, Santamaría M, Martín-Hernández R, Marín FR, Reglero G and Soler-Rivas C: Modulation of cholesterol-related gene expression by dietary fiber fractions from edible mushrooms. J Agric Food Chem 63: 7371-7380, 2015.
37. Barsanti L, Passarelli V, Evangelista V, Frassanito AM and Gualtieri P: Chemistry, physico-chemistry and applications linked to biological activities of β-glucans. Nat Prod Rep 28: 457-466, 2011.
38. Anderson JW, Baird P, Davis RH Jr, Ferreri S, Knudtson M, Koraym A, Waters V and Williams CL: Health benefits of dietary fiber. Nutr Rev 67: 188-205, 2009.
39. Van Horn L, McCoin M, Kris-Etherton PM, Burke F, Carson JA, Champagne CM, Karmally W and Sikand G: The evidence for dietary prevention and treatment of cardiovascular disease. J Am Diet Assoc 108: 287-331, 2008.
40. Vetvicka V and Vetvickova J: Effects of yeast-derived beta-glucans on blood cholesterol and macrophage functionality. J Immunotoxicol 6: 30-35, 2009.
41. de Groot A, Luyken R and Pikaar NA: Cholesterol-lowering effect of rolled oats. Lancet 2: 303-304, 1963.
42. Czop JK: The role of beta-glucan receptors on blood and tissue leukocytes in phagocytosis and metabolic activation. Pathol Immunopathol Res 5: 286-296, 1986.
43. Estrada A, Yun CH, Van Kessel A, Li B, Hauta S and Laarveld B: Immunomodulatory activities of oat beta-glucan in vitro and in vivo. Microbiol Immunol 41: 991-998, 1997.
44. Torrence PF: Biological response modifiers: New approaches to disease intervention. Academic Press, Orlando, pp397, 1985.
45. Novak M and Vetvicka V: Beta-glucans, history, and the present: Immunomodulatory aspects and mechanisms of action. J Immunotoxicol 5: 47-57, 2008.
46. Vetvicka V and Vetvickova J: β1, 3-Glucan: Silver bullet or hot air? Open Glycoscience 3: 1-6, 2010.
47. Vetvicka V and Vetvickova J: Comparison of immunological effects of commercially available β-glucans: Part III. Int J Clin Pathol 2, 2006. doi:10.15406/icpjl.2016.02.00046.
48. Wörsch P and Pi-Sunyer FX: The role of viscous soluble fiber in the metabolic control of diabetes. A review with special emphasis on cereals rich in beta-glucan. Diabetes Care 20: 1774-1780, 1997.
49. Mosikanon K, Arthan D, Kettawan A, Tungtrongchitr R and Prangthip P: Yeast β-glucan modulates inflammation and waist circumference in overweight and obese subjects. J D iet Suppl 14: 173-185, 2017.
50. Browder W, Williams D, Lucore P, Pretus H, Jones E and McNamee R: Effect of enhanced macrophage function on early wound healing. Surgery 104: 224-230, 1988.
51. Vetvicka V and Vetvickova J: Anti-stress action of an orally-given combination of resveratrol, β-glucan, and vitamin C . Molecules 19: 13724-13734, 2014.
52. Vetvicka V and Vetvickova J: β-glucan attenuates chronic fatigue syndrome in murine model. J Nat Sci 1: e112, 2015.
53. Sima P, Vannucci L and Vetvicka V: Glucans and cancer: Historical perspective. Cancer Translational Med 1: 209-214, 2015.
54. Barbieri A, Quagliariello V, Del Vecchio V, Falco M, Luciano A, Amruthraj NJ, Nasti G, Ottaiano A, Berretta M, Iaffaioli RV and Arra C: Anticancer and anti-inflammatory properties of ganoderma lucidum extract effects on melanoma and triple-negative breast cancer treatment. Nutrients 9: pii:E210, 2017.
55. Richter J, Kral V, Svozil V, Rajnohova DL, Pohorska JI and Vetvicka V: Effects of transfer point glucan #300 supplementation on children exposed to passive smoking-placebo-driven double-blind clinical trials. J Nutr Health 1: 105, 2014.
56. Vetvicka V, Richter J, Svozil V, Rajnohovα Dobiαovα L and Krαl V: Placebo-driven clinical trials of yeast-derived β-(1-3) glucan in children with chronic respiratory problems. Ann Transl Med 1: 26, 2013.
57. Brown GD and Gordon S: Immune recognition. A new receptor for beta-glucans. Nature 413: 36-37, 2001.
58. Stambach NS and Taylor ME: Characterization of carbohydrate recognition by langerin, a C-Type lectin of Langerhans cells. Glycobiology 13: 401-410, 2003.
59. Allendorf DJ, Ostroff GR, BAran JT, et al: Oral WGP beta glucan treatment accelerates myeloid recovery and survival after irradiation wxposure. BTR 2003: Unified Science & Technology for Reducing Biological Threats & Counterin Terrorism., Albuquesrque: University of New Mexico, pp104-113, 2003.
60. Ross GD and Větvicka V: CR3 (CD 11b. CD 18): A phagocyte and NK cell membrane receptor with multiple ligand specificities and functions. Cell Exp Immunol 92: 181-184, 1993.
61. Xia Y, Vetvicka V, Yan J, Hanikyrová M, Mayadas T and Ross GD: The beta-glucan-binding lectin site of mouse CR3 (CD 11b/CD 18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J Immunol 162: 2281-2290, 1999.
62. Legentil L, Paris F, Ballet C, Trouvelot S, Daire X, Vetvicka V and Ferrières V: Molecular interactions of β-(1→>3)-glucans with their receptors. Molecules 20: 9745-9766, 2015.
63. Williams DL, Ha T, Li C, Laffan J, Kalbfleisch J and Browder W: Inhibition of LPS-induced NFkappaB activation by a glucan ligand involves down-regulation of IKKbeta kinase activity and altered phosphorylation and degradation of IkappaBalpha. Shock 13: 446-452, 2000.
64. Rogers NC, Slack EC, Edwards AD, Nolte MA, Schulz O, Schweighoffer E, Williams DL, Gordon S, Tybulewicz VL, Brown GD and Reis e Sousa C: Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity 22: 507-517, 2005.
65. Elcombe SE, Naqvi S, Van Den Bosch MW, MacKenzie KF, Cianfanelli F, Brown GD and Arthur JS: Dectin-1 regulates IL-10 production via a MSK1/2 and CREB dependent pathway and promotes the induction of regulatory macrophage markers. PLoS One 8: e60086, 2013.
66. Větvička V: (Beta)-glucans as natural biological response modifiers. Nova Science Publishers, Inc., New York, 2013.
67. Orth M and Bellosta S: Cholesterol: Its regulation and role in central nervous system disorders. Cholesterol 2012: 292598, 2012.
68. Li T and Chiang JY: Regulation of bile acid and cholesterol metabolism by PPARs. PPAR Res 2009: 501739, 2009.
69. Worthmann A, John C, Röhlemann MC, Baguhl M, Heinsen FA, Schaltenberg N, Heine M, Schlein C, Evangelakos I, Mineo C, et al: Cold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis. Nat Med 23: 839-849, 2017.
70. Li T and Chiang JY: Bile acids as metabolic regulators. Curr Opin Gastroenterol 31: 159-165, 2015.
71. Brown MS and Goldstein JL: How LDL receptors influence cholesterol and atherosclerosis. Sci Am 251: 58-66, 1984.
72. Russell D W: The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 72: 137-174, 2003.
73. Kuipers F, Bloks VW and Groen AK: Beyond intestinal soap-bile acids in metabolic control. Nat Rev Endocrinol 10: 488-498, 2014.
74. Gibbons GF, Wiggins D, Brown AM and Hebbachi AM: Synthesis and function of hepatic very-low-density-lipoprotein. Biochem Soc Trans 32: 59-64, 2004.
75. Davidson WS and Hilliard GM: The spatial organization of apolipoprotein A-I on the edge of discoidal high density lipoprotein particles. J Biol Chem 278: 27199-27207, 2003.
76. de Oliveira Alvim R, Mourao-Junior CA, Magalhaes GL, de Oliveira CM, Krieger JE, Mill JG and Pereira AC: Non-HDL cholesterol is a good predictor of the risk of incfeased arterial stiffness in postmenopausal women in an urban Brazilian population. Clinics (Sao Paulo) 72: 106-110, 2017.
77. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S and Tyroler HA: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79: 8-15, 1989.
78. Srinivasan SR, Myers L and Berenson GS: Distribution and correlates of non-high-density lipoprotein cholesterol in children: The Bogalusa heart study. Pediatrics 110: e29, 2002.
79. Hoenig MR: Implications of the obesity epidemic for lipid-lowering therapy: Non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target. Vasc Health Risk Manag 4: 143-156, 2008.
80. The National Cholesterol Education Program (https://www.nhl bi.nih.gov/files/docs/guidelines/atglance.pdf).
81. Masson D, Koseki M, Ishibashi M, Larson CJ, Miller SG, King BD and Tall AR: Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler Thromb Vasc Biol 29: 2054-2060, 2009.
82. White CR, Garber DW and Anantharamaiah GM: Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: A review. J Lipid Res 55: 2007-2021, 2014.
83. Parathasarathy S, Raghavamenon A, Garelnabi MO and Santanam N: Oxidized low-density lipoprotein. Methods Mol Biol 610: 403-417, 2010.
84. Besler C, Löscher TF and Landmesser U: Molecular mechanisms of vascular effects of high-density lipoprotein: Alternations in cardiovascular disease. EMBO Mol Med 4: 251-268, 2012.
85. Stary HC: The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life. Eur Heart J 11 (Suppl E): S3-S19, 1990.
86. Sullivan MP, Cerda JJ, Robbins FL, Burgin CW and Beatty RJ: The gerbil, hamster, and guinea pig as rodent models for hyperlipidemia. Lab Anim Sci 43: 575-578, 1993.
87. Sima A, Stancu C, Constantinescu E, Ologeanu L and Simionescu M: The hyperlipemic hamster-A model for testing the anti-Atherogenic effect of amlodipine. J Cell Mol Med 5: 153-162, 2001.
88. Ohmura H, Fukushima Y, Mizuno A, Niwa K, Kobayashi Y, Ebina T, Kimura K, Ishibashi S and Daida H; Research Committee on Primary Hyperlipidemia of the Ministry of Health and Welfare of Japan: Estimated prevalence of heterozygous familial hypercholesterolemia in patients with acute coronary syndrome. Int Heart J 58: 88-94, 2017.
89. Rosenson RS, Brewer HB Jr, Ansell BJ, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR and Webb NR: Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol 13: 48-60, 2016.
90. Gistera A and Hansson GK: The immunology of atherosclerosis. Nat Rev Nephrol 13: 368-380, 2017.
91. Jonsson AL and Bäckhed F: Role of gut microbiota in atherosclerosis. Nat Rev Cardiol 14: 79-87, 2017.
92. Babicek K, Cehová I, Simon RR, Harwood M and Cox D J: Toxicological assesment of a particulate yeast (1, 3/1, 6)-beta-D-glucan in rats. Food Chem Toxicol 45: 1719-1730, 2007.
93. Brown L, Rosner B, Willett WW and Sacks FM: Cholesterol-lowering effects of dietary fiber: A meta-Analysis. Am J Clin Nutr 69: 30-42, 1999.
94. Phillips GO and Cui SW: An introduction: Evolution and finalisation of the regulatory definition of dietary fibre. Food Hydrocolloids 25: 139-143, 2011.
95. Slavin JL: Dietary fiber and body weight. Nutrition 21: 411-418, 2005.
96. Cheung PCK: Mini-review on edible mushrooms as source of dietary fiber: Preparation and health benefits. Food Sci Human Wellness 2: 162-166, 2013.
97. Jenkins DJ, Kendall CW, Axelsen M, Augustin LS and Vuksan V: Viscous and nonviscous fibres, nonabsorbable and low glycaemic index carbohydrates, blood lipids and coronary heart disease. Curr Opin Lipidol 11: 49-56, 2000.
98. Gee JM, Blackburn NA and Johnson IT: The influence of guar gum on intestinal cholesterol transport in the rat. Br J Nutr 50: 215-224, 1983.
99. Chau CF and Huang YL: Effects of the insoluble fiber derived from Passiflora edulis seed on plasma and hepatic lipids and fecal output. Mol Nutr Food Res 49: 786-790, 2005.
100. Cho IJ, Lee C and Ha TY: Hypolipidemic effect of soluble fiber isolated from seeds of Cassia tora Linn. In rats fed a high-cholesterol diet. J Agric Food Chem 55: 1592-1596, 2007.
101. Zacherl C, Eisner P and Engel KH: In vitro model to correlate viscosity and bile acid-binding capacity of digested water-soluble and insoluble dietary fibres. Food Chem 126: 423-428, 2011.
102. Aoki S, Iwai A, Kawata K, Muramatsu D, Uchiyama H, Okabe M, Ikesue M, Maeda N and Uede T: Oral administration of the Aureobasidium pullulans-derived β-glucan effectively prevents the development of high fat diet-induced fatty liver in mice. Sci Rep 5: 10457, 2015.
103. Steinberg GR and Kemp BE: AMPK in health and disease. Physiol Rev 89: 1025-1078, 2009.
104. Kaczmarczyk MM, Miller MJ and Freund GG: The health benefits of dietary fiber: Beyond the usual suspects of type 2 diabetes mellitus, cardiovascular disease and colon cancer. Metabolism 61: 1058-1066, 2012.
105. Drew BG, Fidge NH, Gallon-Beaumier G, Kemp BE and Kingwell BA: High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc Natl Acad Sci USA 101: 6999-7004, 2004.
106. Roy CC , Kien C L, Bouthillier L and Levy E: Short-chain fatty acids: Ready for prime time? Nutr Clin Pract 21: 351-366, 2006.
107. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ and Bakker BM: The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res 54: 2325-2340, 2013.
108. Chan GC, Chan WK and Sze DM: The effects of beta-glucan on human immune and cancer cells. J Hematol Oncol 2: 25, 2009.
109. Al-Lahham SH, Peppelenbosch MP, Roelofsen H, Vonk RJ and Venema K: Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanisms. Biochim Biophys Acta 1801: 1175-1183, 2010.
110. Wismar R, Brix S, Frøkiaer H and Laerke HN: Dietary fibers as immunoregulatory compounds in health and disease. Ann NY Acad Sci 1190: 70-85, 2010.
111. Vangaveti V, Shashidhar V, Jarrod G, Baune BT and Kennedy RL: Free fatty acid receptors: Emerging targets for treatment of diabetes and its complications. Ther Adv Endocrinol Metab 1: 165-175, 2010.
112. Warnberg J, Gomez-Martinez S, Romeo J, Diaz LE and Marcos A: Nutrition, inflammation, and cognitive function. Ann N Y Acad Sci 1153: 164-175, 2009.
113. Cosola C, De Angelis M, Rocchetti MT, Montemurno E, Maranzano V, Dalfino G, Manno C, Zito A, Gesualdo M, Ciccone MM, et al: Beta-glucans supplementation associates with reduction in P-C resyl sulfate levels and improved endothelial vascular reactivity in healthy individuals. PLoS One 12: e0169635, 2017.
114. Mansbach C M II and Gorelick F: Development and physiological regulation of intestinal lipid absorption. II. Dietary lipid absorption, complex lipid synthesis, and the intracellular packaging and secretion of chylomicrons. Am J Physiol Gastrointest Liver Physiol 293: G645-G650, 2007.
115. Black DD : Development and physiological regulation of intestinal lipid absorption. I. Development of intestinal lipid absorption: Cellular events in chylomicron assembly and secretion. Am J Physiol Gastrointest Liver Physiol 293: G519-G524, 2007.
116. Brown MS and Goldstein JL: The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89: 331-340, 1997.
117. Sato R: Sterol metabolism and SREBP activation. Arch Biochem Biophys 501: 177-181, 2010.
118. Drozdowski LA, Reimer RA, Temelli F, Bell RC, Vasanthan T and Thomson AB: Beta-glucan extracts inhibit the in vitro intestinal uptake of long-chain fatty acids and cholesterol and down-regulate genes involved in lipogenesis and lipid transport in rats. J Nutr Biochem 21: 695-701, 2010.
119. Chen J and Huang XF: The effects of diets enriched in beta-glucans on blood lipoprotein concentrations. J C lin Lipidol 3: 154-158, 2009.
120. Rondanelli M, Opizzi A, Monteferrario F, Klersy C, Cazzola R and Cestaro B: Beta-glucan-or rice bran-enriched foods: A comparative crossover clinical trial on lipidic pattern in mildly hypercholesterolemic men. Eur J Clin Nutr 65: 864-871, 2011.
121. Wolever TM, Tosh SM, Gibbs AL, Brand-Miller J, Duncan AM, Hart V, Lamarche B, Thomson BA, Duss R and Wood PJ: Physicochemical properties of oat β-glucan influence its ability to reduce serum LDL cholesterol in humans: A randomized clinical trial. Am J Clin Nutr 92: 723-732, 2010.
122. Johnson IT and Gee JM: Effect of gel-forming gums on the intestinal unstirred layer and sugar transport in vitro. Gut 22: 398-403, 1981.
123. Kirby RW, Anderson JW, Sieling B, Rees ED, Chen WJ, Miller RE and Kay RM: Oat-bran intake selectively lowers serum low-density lipoprotein cholesterol concentrations of hypercholesterolemic men. Am J Clin Nutr 34: 824-829, 1981.
124. Fadel JG, Newman RK, Newman CW and Barnes AE: Hypocholesterolemic effects of beta-glucans in different barley diets fed to broiler chicks. Nutr Rep Int 35: 1049-1058, 1987.
125. Li J, Kaneko T, Qin LQ, Wang J, Wang Y and Sato A: Long-Term effects of high dietary fiber intake on glucose tolerance and lipid metabolism in GK rats: Comparison among barley, rice, and cornstarch. Metabolism 52: 1206-1210, 2003.
126. Sima A, Bulla A and Simionescu N: Experimental obstructive coronary atherosclerosis in the hyperlipidemic hamster. J Submicrosc Cytol Pathol 22: 1-16, 1990.
127. Lim MK, Ku SK, Choi JS and Kim JW: Effect of polycan, a β-glucan originating from Aureobasidium, on a high-fat diet-induced hyperlipemic hamster model. Exp Ther Med 9: 1369-1378, 2015.
128. Delaney B, Nicolosi RJ, Wilson TA, Carlson T, Frazer S, Zheng GH, Hess R, Ostergren K, Haworth J and Knutson N: Beta-glucan fractions from barley and oats are similarly antiatherogenic in hypercholesterolemic Syrian golden hamsters. J Nutr 133: 468-475, 2003.
129. Wilson TA, Nicolosi RJ, Delaney B, Chadwell K, Moolchandani V, Kotyla T, Ponduru S, Zheng GH, Hess R, Knutson N, et al: Reduced and high molecular weight barley beta-glucans decrease plasma total and non-HDL-cholesterol in hypercholesterolemic Syrian golden hamsters. J Nutr 134: 2617-2622, 2004.
130. Wu YS, Ho SY, Nan FH and Chen SN: Ganoderma lucidum beta 1, 3/1, 6 glucan as an immunomodulator in inflammation induced by a high-cholesterol diet. BMC Complement Altern Med 16: 500, 2016.
131. Kusmiati and Dhewantara FX: Cholesterol-lowering effect of beta glucan extracted from Saccharomyces cerevisiae in rats. Sci Pharm 84: 153-165, 2016.
132. Tong LT, Zhong K, Liu L, Zhou X, Qiu J and Zhou S: Effects of dietary hull-less barley β-glucan on the cholesterol metabolism of hypercholesterolemic hamsters. Food Chem 169: 344-349, 2015.
133. Vetvicka V and Vetvickova J: Physiological effects of different types of beta-glucan. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 151: 225-231, 2007.
134. Malkki Y: Oat fiber. In: Food Science and Technology: Handbook of Dietary Fiber, Cho S and Dreher ML (eds). M. Dekker, New York, pp497-512, 2001.
135. Veniant MM, Withycombe S and Young SG: Lipoprotein size and atherosclerosis susceptibility in Apoe-/-And Ldlr-/-mice. Arterioscler Thromb Vasc Biol 21: 1567-1570, 2001.
136. Pendse AA, Arbones-Mainar JM, Johnson LA, Altenburg MK and Maeda N: Apolipoprotein E knock-out and knock-in mice: Atherosclerosis, metabolic syndrome, and beyond. J Lipid Res 50 (Suppl): S178-S182, 2009.
137. Anderson JW, Story L, Sieling B, Chen WJ, Petro MS and Story J: Hypocholesterolemic effects of oat-bran or bean intake for hypercholesterolemic men. Am J Clin Nutr 40: 1146-1155, 1984.
138. Anderson JW and Gustafson NJ: Hypocholesterolemic effects of oat and bean products. Am J Clin Nutr 48 (Suppl 3): S749-S753, 1988.
139. Braaten JT, Wood PJ, Scott FW, Wolynetz MS, Lowe MK, Bradley-White P and Collins MW: Oat beta-glucan reduces blood cholesterol concentration in hypercholesterolemic subjects. Eur J Clin Nutr 48: 465-474, 1994.
140. Newman RK, Lewis SE, Newman CW, Boik RJ and Ramage RT: Hypocholesterolemic effect of barley foods on healthy men. Nutr Rep Int 39: 749-760, 1989.
141. McIntosh GH, Whyte J, McArthur R and Nestel PJ: Barley and wheat foods: Influence on plasma cholesterol concentrations in hypercholesterolemic men. Am J Clin Nutr 53: 1205-1209, 1991.
142. Lupton JR, Robinson MC and Morin JL: Cholesterol-lowering effect of barley bran flour and oil. J Am Diet Assoc 94: 65-70, 1994.
143. Lia A, Hallmans G, Sandberg AS, Sundberg B, Aman P and Anderson H: Oat beta-glucan increases bile excretion and a fiber rich barley fracton increases cholesterol excretion in ileostomy subjects. Am J Clin Nutr 62: 1245-1251, 1995.
144. Bell S, Goldman VM, Bistrian BR, Arnold AH, Ostroff G and Forse RA: Effect of beta-glucan from oats and yeast on serum lipids. Crit Rev Food Sci Nutr 39: 189-202, 1999.
145. Li J, Kaneko T, Qin LQ, Wang J and Wang Y: Effects of barley intake on glucose tolerance, lipid metabolism, and bowel function in women. Nutrition 19: 926-929, 2003.
146. Behall KM, Scholfield DJ and Hallfrisch J: Diets containing barley significantly reduce lipids in mildly hypercholesterolemic men and women. Am J Clin Nutr 80: 1185-1193, 2004.
147. Behall KM, Scholfield DJ and Hallfrisch J: Lipids significantly reduced by diets containing barley in moderately hypercholesterolemic men. J Am Coll Nutr 23: 55-62, 2004.
148. Keenan JM, Goulson M, Shamliyan T, Knutson N, Kolberg L and Curry L: The effects of concentrated barley beta-glucan on blood lipids in a population of hypercholesterolaemic men and women. Br J Nutr 97: 1162-1168, 2007.
149. Shimizu C, Kihara M, Aoe S, Araki S, Ito K, Hayashi K, Watari J, Sakata Y and Ikegami S: Effect of high beta-glucan barley on serum cholesterol concentrations and visceral fat area in Japanese men-A randomized, double-blinded, placebo-controlled trial. Plant Foods Hum Nutr 63: 21-25, 2008.
150. Sundberg B: Cholesterol lowering effects of a barley fibre flake product. Agro Food Industry Hi-Tech 19: 14-17, 2008.
151. Zhu X, Sun X, Wang M, Zhang C, Cao Y, Mo G, Liang J and Zhu S: Quantitative assessment of the effects of beta-glucan consumption on serum lipid profile and glucose level in hypercholesterolemic subjects. Nutr Metab Cardiovasc Dis 25: 714-723, 2015.
152. Keogh GF, Cooper GJ, Mulvey TB, McArdle BH, Coles GD, Monro JA and Poppitt SD: Randomized controlled crossover study of the effect of a highly beta-glucan-enriched barley on cardiovascular disease risk factors in mildly hypercholesterolemic men. Am J Clin Nutr 78: 711-718, 2003.
153. Biörklund M, van Rees A, Mensink RP and Onning G: Changes in serum lipids and postprandial glucose and insulin concentrations after consumption of beverages with beta-glucans from oats or barley: A randomised dose-controlled trial. Eur J Clin Nutr 59: 1272-1281, 2005.
154. Ibrógger S, Kristensen M, Poulsen MW, Mikkelsen MS, Ejsing J, Jespersen BM, Dragsted LO, Engelsen SB and Bógel S: Extracted oat and barley β-glucans do not affect cholesterol metabolism in young healthy adults. J Nutr 143: 1579-1585, 2013.
155. Talati R, Baker WL, Pabilonia MS, White CM and Coleman CI: The effects of barley-derived soluble fiber on serum lipids. Ann Fam Med 7: 157-163, 2009.
156. AbuMweis SS, Jew S and Ames NP: β-glucan from barley and its lipid-lowering capacity: A meta-Analysis of randomized, controlled trials. Eur J Clin Nutr 64: 1472-1480, 2010.
157. Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GB, McPherson R, Francis GA, Poirier P, Lau DC , Grover S, et al: 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 29: 151-167, 2013.
158. Newman RK and Newman CW: Barley for food and health: Science, technology, and products. In: Genetics and Nutrient Composition John Wiley & Sons, Hoboken, NJ, pp56-94, 2008.
159. Ho HV, Sievenpiper JL, Zurbau A, Blanco Mejia S, Jovanovski E, Au-Yeung F, Jenkins AL and Vuksan V: A systematic review and meta-Analysis of randomized controlled trials of the effect of barley β-glucan on LDL-C , non-HDL-C and apoB for cardiovascular disease risk reductioni-iv. Eur J Clin Nutr 70: 1340, 2016.
160. Mori K, Kobayashi C, Tomita T, Inatomi S and Ikeda M: Antiatherosclerotic effect of the edible mushrooms Pleurotus eryngii (Eringi), Grifola frondosa (Maitake), and Hypsizygus marmoreus (Bunashimeji) in apolipoprotein E-deficient mice. Nutr Res 28: 335-342, 2008.
161. Sun JE, Ao ZH, Lu ZM, Xu HY, Zhang XM, Dou WF and Xu ZH: Antihyperglycemic and antilipidperoxidative effects of dry matter of culture broth of Inonotus obliquus in submerged culture on normal and alloxan-diabetes mice. J Ethnopharmacol 118: 7-13, 2008.
162. Bays HE, Evans JL, Maki KC, Evans M, Maquet V, Cooper R and Anderson JW: Chitin-glucan fiber effects on oxidized low-density lipoprotein: A randomized controlled trial. Eur J Clin Nutr 67: 2-7, 2013.
163. Serra-Majem L, Roman B and Estruch R: Scientific evidence of interventions using the Mediterranean diet: A systematic review. Nutr Rev 64 (Suppl): S27-S47, 2006.
164. Wang Y, Harding SV, Eck P, Thandapilly SJ, Gamel TH, Abdel-Aal el-SM, Crow GH, Tosh SM, Jones PJ and Ames NP: High-molecular-weight β-glucan decreases serum cholesterol differentially based on the CYP7A1 rs3808607 polymorphism in mildly hypercholesterolemic adults. J Nutr 146: 720-727, 2016.